biostudies-literatureUnknown15Fowler RACanadian Institutes of Health Research<h4>Background</h4>Venous thromboembolism (VTE) is a common complication of critical illness with important clinical consequences. The Prophylaxis for ThromboEmbolism in Critical Care Trial (PROTECT) is a multicenter, blinded, randomized controlled trial comparing the effectiveness of the two most common pharmocoprevention strategies, unfractionated heparin (UFH) and low molecular weight heparin (LMWH) dalteparin, in medical-surgical patients in the intensive care unit (ICU). E-PROTECT is a prospective and concurrent economic evaluation of the PROTECT trial.<h4>Methods/design</h4>The primary objective of E-PROTECT is to identify and quantify the total (direct and indirect, variable and fixed) costs associated with the management of critically ill patients participating in the PROTECT trialTrials502https://www.ebi.ac.uk/biostudies/studies/S-EPMC4413997biostudies-literatureEconomic evaluation of the prophylaxis for thromboembolism in critical care trial (E-PROTECT): study protocol for a randomized controlled trial.PMC4413997Muscedere JGeerts WHPinto RCooper JMarshall JCSeppelt IAustralia and New Zealand Intensive Care Society Clinical Trials GroupKlinger JRGuyatt GCade JFCanadian Critical Care Trials GroupOrmanidhi OOrford NSkrobik YKDoig CJMehta SSud SMcIntyre LJacka MJCook DFowler RADodek PHall RKrahn MQushmaq IChan BMittmann NArabi YRocha MGGould MKFinfer SHeels-Ansdell DFerguson NDVlahakis NfalseEconomic evaluation of the prophylaxis for thromboembolism in critical care trial (E-PROTECT): study protocol for a randomized controlled trial.<h4>Background</h4>Venous thromboembolism (VTE) is a common complication of critical illness with important clinical consequences. The Prophylaxis for ThromboEmbolism in Critical Care Trial (PROTECT) is a multicenter, blinded, randomized controlled trial comparing the effectiveness of the two most common pharmocoprevention strategies, unfractionated heparin (UFH) and low molecular weight heparin (LMWH) dalteparin, in medical-surgical patients in the intensive care unit (ICU). E-PROTECT is a prospective and concurrent economic evaluation of the PROTECT trial.<h4>Methods/design</h4>The primary objective of E-PROTECT is to identify and quantify the total (direct and indirect, variable and fixed) costs associated with the management of critically ill patients participating in the PROTECT trial2014-01-01T00:00:00Z2014 Dec2026-04-28T23:26:13.285Z2019-03-27T01:50:43ZS-EPMC44139972552866310.1186/1745-6215-15-50210.1186/1745-6215-15-209